Renovo Group plc was a biopharmaceutical company founded in 1998 and headquartered in Manchester, United Kingdom. It worked in the discovery and development of drugs to reduce scarring, improve wound healing and enhance tissue regeneration.[1] Renovo does not currently have any marketed products. It aimed "to be first to market with a scar prevention pharmaceutical drug in the US and Europe" in approximately 2014. Following the failure of its last clinical candidate, Juvista, all 100 of Renovo's staff were laid off in 2011.[2][3][4]
Although the company stopped all pharmaceutical development, it continued as a financial provider. In August 2014, Renovo Group plc was renamed Inspired Capital plc.[5][6]
Products
Renovo does not currently have any marketed products. Its development pipeline currently includes one drug in phase III clinical development, two in phase II clinical development, and numerous pre-clinical candidates.[7]
External links
References
- London Regenerative Medicine Network – January 2007 Meeting^
- Renovo Group founder to become Science Foundation Ireland's boss (9 January 2012). Manchester Evening News.^
- Pharma Times Just 10% of workforce left at Renovo after Juvista failure (4 March 2011). Pharmatimes.com.^
- Kevin Grogan. Future bleak for Renovo with no workers or products PharmaTimes, 31 May 2001, retrieved 14 December 2016^
- Rename Plan for Renovo (16 July 2014). InsiderMedia.com^
- Company Overview of Inspired Capital plc Bloomberg, retrieved 14 December 2016^
- Renovo – Products^
- "Pharma Times" Just 10% of workforce left at Renovo after Juvista failure (4 March 2011). Pharmatimes.com.^
- Ashcroft, Jamie. (18 November 2011) "ProactiveInvestors" – Renovo ends Adaprev development (18 November 2011). Proactiveinvestors.co.uk.^
- Ashcroft, Jamie. (16 April 2012) "ProactiveInvestor" Renovo ends Prevascar development (16 April 2012). Proactiveinvestors.co.uk.^